NICE Backs First Immunotherapy for Resectable Gastric Cancer Edited by Joyani Das Medscape UK May 15, 2026

https://www.medscape.com/viewarticle/nice-backs-first-immunotherapy-resectable-gastric-cancer-2026a1000frm The National Institute for Health and Care Excellence (NICE) has recommended durvalumab (Imfinzi, AstraZeneca) as the first immunotherapy option for adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.